By the year 2050, the number of Americans living with Alzheimer’s disease is expected to triple to 14 million people.

The dramatic rise in 2050 is expected to cost American society $1 trillion in today’s dollars. $1 trillion would include a nearly FIVE-FOLD increase in government spending in Medicare and Medicaid.

In 2016, one in every five Medicare dollars was spent on Alzheimer’s and other dementias. By 2050, it will be one in every three and every 33 seconds, another American will be diagnosed with Alzheimer’s.

Yet, no drugs available today slow or stop Alzheimer’s damage to neurons. Few new drugs are in clinical trials. The failure rate of clinical trials of new drugs has been more than 99%.

That’s one of the lowest success rates in any therapy.

So, researchers have shifted their focus from treating Alzheimer’s to preventing it. And, according to a new study, aspirin could possibly be the answer.

Click here to read the Newsweek story.